FierceBiotech’s Maureen Martino has produced a “special report” on four biotech drugs poised for approval later this year that could be “the next generation of biologic blockbusters” — that is, treatments that not only pull in more than $1 billion in annual sales, but which “could offer real breakthroughs for patients” while “add[ing]...
Pharma Industry Archive
July 2008
Earlier this week, the WSJ noted that oncologists are getting squeezed on the cost of expensive cancer drugs. Although the story features the usual anecdotes of doctors whose practices are in debt or who are shunting patients off to hospitals for treatment in order to save money, it’s still hard to feel too sorry for them, because until recently cancer specialists were able to make a...
When AstraZeneca ponied up more than $15 billion for the biotech MedImmune just over a year ago, the deal suggested that desperate Big Pharmas were willing to open their wallets wide for biotechs without looking too closely into the question of whether they were really worth the money. As I suggested at the time, it wasn’t at all clear that AstraZeneca knew what it was getting into, and...
Gen-Probe, which a month ago launched a risky takeover bid for the Belgian diagnostics maker Innogenetics, did indeed spark a counteroffer from Dutch drugmaker Solvay Pharmaceuticals and now appears to have given up. As bidding wars go, this one was something of a flop: The Dutch company topped Gen-Probe’s €6.10 ($9.60) per-share offer by just 6.5 percent, or €6.50, after which...
Pfizer is one of the biggest pharmas around, but it’s also facing more serious trouble in the near term than just about anyone else, mostly thanks to the impending demise of its Lipitor franchise. Now it looks like the drugmaker is planning some significant changes, which may add up to something big. Consider the following hints, not all of which are confirmed: Several reports last week...
The pharmaceutical industry is finally facing one of its worst-case scenarios: FDA’s drug-safety officials will now hold considerably more sway over both experimental and approved drugs. Prodded by Congress in the wake of several major drug-safety and effectiveness concerns – starting, perhaps, with Vioxx, and since expanded to several antidepressants, Avandia, Vytorin, Chantrix...
The failure of Myriad Genetics‘ experimental Alzheimer’s drug Flurizan is surely unfortunate news for those with the disease and their families, but it also reflects badly on the Danish pharma H. Lundbeck, which paid Myriad $100 million on May 22 for European rights to the drug. Since Myriad has discontinued work on Flurizan, that’s $100 million that Lundbeck and its...
- Novartis Looks at Combination Pills to Fix Hypertension Franchise
- Study Showing Drug Ads Are Linked to Higher Prices Has Flaws
- Bankers Reveal Top Biotech IPO Contenders; New Filer Ironwood Among Them
- Pfizer Got $160M in Tax Money to Build in Connecticut
- Sanofi's Viehbacher Backs Health Reform; May Change Company's Name
- Viagra Now Available Intravenously
- Genzyme Kidney Drug Failed, Too...What Could Possibly Happen Next?
- Peter Pitts' CMPI Targeted Over Anti-Healthcare Reform Video Game
- Why Allergan and Medicis Should Embrace the "Botox Tax" in Senate Health Bill
- Why J&J's Stelara Launch Should Target Dermatologists First
- NHS Loses Fight Over Publication of Antipsychotic Meds Brochures for Kids
- Genzyme's Termeer Got $50M in Compensation Over Last 3 Years; Wife Got Trips to Asia on Corporate Jet
- Merck Gives Snapshot of Combined Company: $47B in Sales; Just $7.6B in Cash
- Why Pfizer Wants Your Car-Sick Dog to Travel on Thanksgiving
- FDA Delays Genzyme's Lumizyme, Manufacturing Problems Blamed
- Will FDA Approve MannKind's Insulin Inhaler?
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted
- Hepatitis C Drugs Kill the Virus...and Your Sex Drive
- Microchip Implant to Link Your Health Records, Credit History, Social Security
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching
- NYT's MannKind Story Needlessly Quoted a Competitor Bashing Afresa
- Novartis CEO Sends Emails to 140 Animal Rights Activists:
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low
Subscribe to Pharma blog comments RSS 
- How NOT to Write a Biotech Press Release: Just Ask Epeius
- The 10 Weirdest Drug Stories of the Month
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity"
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted
Industry Transcripts by Seeking Alpha
- How to choose the right insurance carrier for your business
- Real Estate: Prepare your properties to weather what lies ahead
- Technology: Be prepared if part of your global supply chain goes missing
Archives
Recommended Sources
About Pharma Industry
BNET Pharma provides daily industry trends and news coverage with insights for managers and executives about major manufacturers of pharmaceuticals and medicine. In addition to detailed drug company profiles, we bring you industry analysis on new partnerships, drug patents and products, cost management, investments, pharmaceutical related lawsuits, and a host of other important business issues.